Cell and Gene Therapy CTDMO
Redefining end to end solutions through integrated development, manufacturing, and testing
For cell and gene therapy companies, outsourcing manufacturing and testing operations to a capable CTDMO can reduce development timelines, provide supplementary capacity, and ultimately control costs. With an assortment of available options, how do you select the right organization?
Through continued internal reinvestment in facilities, technology, and talent combined with over three decades of biopharmaceutical testing expertise, we have transformed our services into solutions that alleviate industry bottlenecks, accelerate time to market, and support commercial programs around the world.
Fast-track time to market
Your Strategic Partner: Overview of CTDMO Capabilities
- Viral Vectors for Gene Therapies
- Autologous and Allogeneic Cell Therapies
- Gene Mediated Cell Therapies like CAR-T
- Emerging technologies like CRISPR/Cas9, Oncolytic Viruses, NK’s, and Exosomes
D in Development
GMP Manufacturing Capacity
In-Process QC and Release Testing – Integrated or Stand Alone
Infrastructure to Access New Markets
When launching a product in a new market, a local CTDMO can be a significant asset. To support the second largest market, new GMP facilities in Shanghai and WuXi City will be online shortly.
Not sure what Manufacturing or Testing service is right for you? Speak to our experts.